FOLR1 and endometrial cancer: This phase I study investigated MIRV in combination with gemcitabine in patients with FRα-positive recurrent EOC, primary peritoneal cancer, fallopian tube cancer, endometrial cancer, or triple-negative breast cancer, with the aim of defining a tolerable dosing regimen and assessing safety.